Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology
Emerald study met both its primary end points of Progression-free survival (PFS) in overall population and in ESR1 mutated patients PFS rate at 12 months with elacestrant was 22.32% vs. 9.42% with SOC in the overall population, and 26.76% vs. 8.19% in the ESR1 mutation population Data demonstrated elacestrant significantly reduced the risk of disease progression or […]
